Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of H5N8 Influenza Vaccine with Adjuvants in Healthy Adults
NCT02624219Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2016
- Primary completion
- Jan 2018
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Influenza A (H5N8) Monovalent Vaccine in Avian Influenza (AI) (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Geometric Mean Titers of serum Hemagglutination Inhibition antibodies at Day 43, Geometric Mean Titers of serum Neutralizing antibodies at Day 43 and 7 more. Started Aug 2016; status: completed.
02
Drugs
Influenza A (H5N8) Monovalent Vaccine
03
Conditions
Avian Influenza (AI)
Beyond the preview
Go deeper on NCT02624219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02624219.